Benzo[d]imidazole-functionalized triazatruxenes as the emitting materials for solution-processed non-doped OLEDs. (April 2021)

• Record Type: Journal Article
• Authors: Zhou, Yang; Li, Yanmei; Wu, Shaoguang; Zhao, Yuling; Yu, Tianzhi; Su, Wenming; Ma, Hailin; Qian, Long; Wang, Ruidong
• Is Part Of: Dyes and pigments. Volume 188(2021)
• Publication Date: 2021-04
• Subjects: TAT -- Triazatruxene -- BI -- Benzo[d]imidazole -- Photoluminescence -- Electroluminescence; Dyes and dyeing -- Periodicals; Pigments -- Periodicals; 667.2
• DOI: 10.1016/j.dyepig.2021.109165
• Languages: English
• ISSNs: 0143-7208

Abstract

Abstract: Two benzo[ d ]imidazole/triazatruxene hybrid compounds, 5, 10, 15-tributyl-2, 7, 12-tris(4-(1-phenyl-1 H -benzo[ d ]imidazole-2-yl)phenyl)-10, 15-dihydro-5 H -diindolo[3, 2- a :3′, 2′-c]carbazole (2, 7, 12-TBI-TAT ) and 5, 10, 15-tributyl-3, 8, 13-tris(4-(1-phenyl-1 H -benzo[ d ]imidazole-2-yl)phenyl)-10, 15-dihydro-5 H -diindolo[3, 2- a :3′, 2′-c]carbazole (3, 8, 13-TBI-TAT ), were synthesized by the introduction of three benzo[ d ]imidazole (BI) moieties at 2-, 7-, 12-positions and 3-, 8-, 13-positions of the alkylated triazatruxene (TAT) core, respectively. Their thermal stabilities, photophysical and electrochemical properties were systematically investigated. These hybrid compounds exhibited good solubility as well as excellent thermal stability. Besides, the solution-processed doped and non-doped OLEDs based on the compounds were fabricated, in which the non-doped device fabricated from 2, 7, 12-TBI-TAT exhibited the best electroluminescence performance with a maximum brightness of 10075 cd/m 2, a maximum current efficiency of 5.35 cd/A and a maximum external quantum efficiency (EQE) of 2.25%. Graphical abstract: Image 1 Highlights: Two benzo[ d ]imidazole/triazatruxene hybrid compounds were synthesized for OLEDs. These hybrid compounds exhibited good solubility as well as excellent thermal stability. The non-doped device based on 2, 7, 12-substituted isomer exhibited the luminous efficiencies of 5.35 cd/A and EQE of 2.25%.